A5057037263- Dermatology and Skin Diseases
- Allergic Rhinitis and Sensitization
- Food Allergy and Anaphylaxis Research
- Asthma and respiratory diseases
- Autoimmune Bullous Skin Diseases
- Vascular Malformations and Hemangiomas
- Cutaneous Melanoma Detection and Management
- Nail Diseases and Treatments
- Cutaneous lymphoproliferative disorders research
- Urticaria and Related Conditions
- Eosinophilic Esophagitis
- Neonatal skin health care
- Contact Dermatitis and Allergies
- Medicine and Dermatology Studies History
- Vascular Malformations Diagnosis and Treatment
- Vascular Tumors and Angiosarcomas
- Psoriasis: Treatment and Pathogenesis
- Parvovirus B19 Infection Studies
- Fungal Infections and Studies
- Genetic and rare skin diseases.
- Nonmelanoma Skin Cancer Studies
- Transgenic Plants and Applications
- Cancer and Skin Lesions
- Tumors and Oncological Cases
- Herbal Medicine Research Studies
Seattle Children's Hospital
2015-2024
University of Washington
2015-2024
Georgetown University
2023
Galderma (United States)
2020
Pacific Northwest University of Health Sciences
2018
National Institute of Allergy and Infectious Diseases
2017
American Academy of Dermatology
2015
Boston Children's Hospital
2008-2015
Fred Hutch Cancer Center
2015
Harvard University Press
2004-2009
Dupilumab subcutaneous injection is approved for treating moderate-to-severe atopic dermatitis (AD) in adolescents, but there has been too little research on an efficacious systemic oral treatment with a favorable benefit-risk profile adolescents AD.To investigate the efficacy and safety of abrocitinib plus topical therapy AD.The phase 3, randomized, double-blind, placebo-controlled study JADE TEEN was conducted countries Asia-Pacific region, Europe, North America patients aged 12 to 17...
Pediatric patients with moderate-to-severe atopic dermatitis (AD) often experience a high disease burden and have risk of persistent disease. Standard-of-care immunosuppressive systemic treatments been used off-label for AD in pediatric despite concerns suboptimal safety continuous use relapse upon discontinuation. The biologic agent dupilumab is the first treatment approved children as young 6 months. Long-term efficacy data this patient population are needed to inform management.
Nemolizumab, a new monoclonal antibody that targets the receptor alpha of neuroimmune cytokine interleukin-31 (IL-31), has shown efficacy in atopic dermatitis (AD) adults. This study evaluated pharmacokinetics (PK) and safety nemolizumab adolescents with moderate to severe AD as well relationship between concentrations clinical effect on protein biomarkers.Open-label, 16-week patients aged 12-17 years (baseline EASI ≥ 16, IGA 3, BSA 10%) associated pruritus baseline average daily peak...
Objectives To outline a safe, standardized protocol for outpatient initiation of propranolol therapy infantile hemangiomas. Study Design Retrospective review. Setting Academic tertiary care pediatric hospital. Subjects and Methods Forty‐nine hemangioma patients were offered included in the study. Any requiring hospital admission excluded. Screening consisted cardiology evaluation, including electrocardiography and, when indicated, echocardiography. Target dose was 2 to 3 mg/kg/d divided into...